125 related articles for article (PubMed ID: 35363106)
1. The association between body mass index and pathological complete response in neoadjuvant-treated breast cancer patients.
Skarping I; Blaabjerg Pedersen S; Förnvik D; Zackrisson S; Borgquist S
Acta Oncol; 2022 Jun; 61(6):731-737. PubMed ID: 35363106
[TBL] [Abstract][Full Text] [Related]
2. Impact of body mass index on pathological complete response following neoadjuvant chemotherapy in operable breast cancer: a meta-analysis.
Wang H; Zhang S; Yee D; Basu S; Beckwith H; Potter D; Blaes A
Breast Cancer; 2021 May; 28(3):618-629. PubMed ID: 33387284
[TBL] [Abstract][Full Text] [Related]
3. Mammographic density as an image-based biomarker of therapy response in neoadjuvant-treated breast cancer patients.
Skarping I; Förnvik D; Heide-Jørgensen U; Sartor H; Hall P; Zackrisson S; Borgquist S
Cancer Causes Control; 2021 Mar; 32(3):251-260. PubMed ID: 33377172
[TBL] [Abstract][Full Text] [Related]
4. Predicting pathological axillary lymph node status with ultrasound following neoadjuvant therapy for breast cancer.
Skarping I; Förnvik D; Zackrisson S; Borgquist S; Rydén L
Breast Cancer Res Treat; 2021 Aug; 189(1):131-144. PubMed ID: 34120224
[TBL] [Abstract][Full Text] [Related]
5. Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial.
Di Cosimo S; Porcu L; Agbor-Tarh D; Cinieri S; Franzoi MA; De Santis MC; Saura C; Huober J; Fumagalli D; Izquierdo M; Piccart M; Daidone MG; de Azambuja E
Breast Cancer Res; 2020 Oct; 22(1):115. PubMed ID: 33109233
[TBL] [Abstract][Full Text] [Related]
6. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
7. Investigating the Association Between Type 2 Diabetes Mellitus and Pathological Responses Among Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.
Javed S; Mohamed Noor DA; Md Hanafiah NH; Javed U; Mustafa T; Rehman AU; Harun SN
J Surg Res; 2024 Jul; 299():85-93. PubMed ID: 38718688
[TBL] [Abstract][Full Text] [Related]
8. New insights into breast microcalcification for poor prognosis: NACT cohort and bone metastasis evaluation cohort.
Hu Y; Mao L; Wang M; Li Z; Li M; Wang C; Ji L; Zeng H; Zhang X
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7285-7297. PubMed ID: 36917189
[TBL] [Abstract][Full Text] [Related]
9. Obesity or overweight is associated with worse pathological response to neoadjuvant chemotherapy among Chinese women with breast cancer.
Chen S; Chen CM; Zhou Y; Zhou RJ; Yu KD; Shao ZM
PLoS One; 2012; 7(7):e41380. PubMed ID: 22848477
[TBL] [Abstract][Full Text] [Related]
10. EarlyR signature predicts response to neoadjuvant chemotherapy in breast cancer.
Buechler SA; Gökmen-Polar Y; Badve SS
Breast; 2019 Feb; 43():74-80. PubMed ID: 30502641
[TBL] [Abstract][Full Text] [Related]
11. The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT): A Review of 20,000 Breast Cancer Patients in the National Cancer Data Base (NCDB).
Fayanju OM; Ren Y; Thomas SM; Greenup RA; Plichta JK; Rosenberger LH; Tamirisa N; Force J; Boughey JC; Hyslop T; Hwang ES
Ann Surg; 2018 Oct; 268(4):591-601. PubMed ID: 30048319
[TBL] [Abstract][Full Text] [Related]
12. The association between body mass index and immunohistochemical subtypes in breast cancer.
Sahin S; Erdem GU; Karatas F; Aytekin A; Sever AR; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():227-236. PubMed ID: 27756509
[TBL] [Abstract][Full Text] [Related]
13. Impact of body mass index on pathological complete response and survival of breast cancer patients receiving neoadjuvant chemotherapy.
Aguiar D; Ros L; Pérez D; Croissier L; Mori M; Hernández M; Vargas AM; Galván S; Antonilli C; Saura S
Breast Dis; 2022; 41(1):351-361. PubMed ID: 36031886
[TBL] [Abstract][Full Text] [Related]
14. Association of the Interaction Between Mammographic Breast Density, Body Mass Index, and Menopausal Status With Breast Cancer Risk Among Korean Women.
Tran TXM; Moon SG; Kim S; Park B
JAMA Netw Open; 2021 Dec; 4(12):e2139161. PubMed ID: 34940866
[TBL] [Abstract][Full Text] [Related]
15. A study on clinico-pathological assessment of response to neoadjuvant chemotherapy in breast carcinoma.
Mohapatra M; Sarma YS
J Cancer Res Ther; 2020; 16(6):1419-1425. PubMed ID: 33342807
[TBL] [Abstract][Full Text] [Related]
16. Effect of Body Mass Index- and Actual Weight-Based Neoadjuvant Chemotherapy Doses on Pathologic Complete Response in Operable Breast Cancer.
Raman R; Mott SL; Schroeder MC; Phadke S; El Masri J; Thomas A
Clin Breast Cancer; 2016 Dec; 16(6):480-486. PubMed ID: 27431461
[TBL] [Abstract][Full Text] [Related]
17. Body mass index, mammographic density, and breast cancer risk by estrogen receptor subtype.
Shieh Y; Scott CG; Jensen MR; Norman AD; Bertrand KA; Pankratz VS; Brandt KR; Visscher DW; Shepherd JA; Tamimi RM; Vachon CM; Kerlikowske K
Breast Cancer Res; 2019 Apr; 21(1):48. PubMed ID: 30944014
[TBL] [Abstract][Full Text] [Related]
18. Mammographic density changes during neoadjuvant breast cancer treatment: NeoDense, a prospective study in Sweden.
Skarping I; Förnvik D; Heide-Jørgensen U; Sartor H; Hall P; Zackrisson S; Borgquist S
Breast; 2020 Oct; 53():33-41. PubMed ID: 32563178
[TBL] [Abstract][Full Text] [Related]
19. Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials.
Fontanella C; Lederer B; Gade S; Vanoppen M; Blohmer JU; Costa SD; Denkert C; Eidtmann H; Gerber B; Hanusch C; Hilfrich J; Huober J; Schneeweiss A; Paepke S; Jackisch C; Mehta K; Nekljudova V; Untch M; Neven P; von Minckwitz G; Loibl S
Breast Cancer Res Treat; 2015 Feb; 150(1):127-39. PubMed ID: 25677740
[TBL] [Abstract][Full Text] [Related]
20. A Multicenter Study of the Impact of Body Mass Index (BMI) on the incidence of Pathologic Complete Response (pCR) Among Saudi Patients with locally advanced Breast cancer (LABC) post Neoadjuvant Chemotherapy (NAC).
Al-Saleh K; Abd El-Aziz N; Ali A; Abo Zeed W; Salah T; Elsamany S; Rasmy A; El Farargy O; Husain S; Al-Rikabi A; Alsaeed E; Aldiab A; Abd El-Warith A
Gulf J Oncolog; 2019 May; 1(30):33-42. PubMed ID: 31242980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
